Business
Aclarion Announces Closing of $14.4 Million Public Offering of Common Stock and Warrants
BROOMFIELD, CO - January 17, 2025 (NEWMEDIAWIRE) - Aclarion, Inc. ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is
About this update from Aclarion, Inc.
[{"type":"text","content":"BROOMFIELD, CO - January 17, 2025 (NEWMEDIAWIRE) - Aclarion, Inc. (\"Aclarion\" or the \"Company\") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of an underwritten public offering of 100,000 shares of common stock and 143,900,000 pre-funded warrants with each share of common stock and each pre-funded warrant accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $0.20 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $0.20 per share. The combined public offering price of each share of common stock together with the accompanying series A and series B common warrants is $0.10, and the combined public offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $0.09999. In addition, the Company granted to the underwriter a 45 day option to purchase up to an additional 21,000,000 shares of its common stock (or pre-funded warrants), at the public offering price, less underwriting discounts and commissions, and up to an additional 21,000,000 series A common warrants and up to an additional 21,000,000 series B common warrants at a nominal price to cover over-allotment sales. The underwriter exercised its option to purchase 21,000,000 series A common warrants and 21,000,000 series B common warrants. All shares of common stock, pre-funded warrants, series A common warrants and series B common warrant were sold by Aclarion. The closing of the public offering occurred on January 16, 2025.\nDawson James Securities, Inc. acted as the sole bookrunning manager for the public offering.\nThe gross proceeds of the public offering were approximately $14.4 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Aclarion. Aclarion intends to use the net proceeds from the offering to redeem all outstanding shares of its Series B Preferred Stock at a redemption price per share equal to $1,000 plus all accrued but unpaid dividends on each such share, with the remaining net proceeds to be used to build out the product platforms, expand its sales and marketing efforts...